Gilad Glick Photo: Eyal Izhar Itamar Medical raises $11.5m

The More Investment House invested in the round, which may be enlarged.

medical device illustration Israeli telehealth co Tyto Care raises $9m

The latest funding recognizes the unique potential of Tyto Care's on-demand, remote telehealth solution to improve healthcare access and delivery in the US, Japan and China.

Isaac Israel  photo: PR Kitov raises $6m after positive cancer drug data

Short exposure of cancerous cells to the Israeli company's NT219 drug is sufficient to trigger irreversible shutdown of cancer pathways.

Nasdaq Photo: Reuters Brainsway files for $30m Nasdaq offering

The company has developed a magnetic helmet for treatment of neurological diseases.

Innovation Authority chair Ami Appelbaum, CEO Aharon Aharon, Economy Minister Eli Cohen Innovation Authority pinpoints Israeli tech industry's failings

In a 100-page survey, the Authority recommends government action to focus the industry on AI and bring its benefits to other sectors.

Pfizer Photo: Reuters CytoReason teams with Pfizer on drug discovery

The Israeli company will earn over $10 million for its machine learning cell-centered models of the immune system.

Teva's Kfar Saba site Photo: Alon Ron Teva to produce new complex drugs outside Israel

Management feels that labor disputes at Teva's Kfar Saba plant have made the site less attractive for production of new drugs.

Leon Lerman and Daniel Brodie Photo; Rachel Morie Hospital cybersecurity co Cynerio raises $7m

The Israeli company is already working in many hospitals throughout Israel including Ichilov and Rambam.

Marius Nacht, photo: Tamar Matsafi aMoon raises $600m for second life sciences fund - Reuters

The Israeli healthcare and life sciences venture capital firm will invest in digital health, medical devices and biopharma in Israel, the US and Europe.

Len Blavatnik Photo: Getty Images Aposense unit to raise $20m from Len Blavatnik

Sirvir will develop treatments for infectious diseases in the respiratory system.

Cancerous cells Photo: Shutterstock Anchiano Therapeutics files for $40m Nasdaq IPO

The company has one product in Phase III trials and another in Phase II trials.

Pharmaceutical laboratory Photo: Shutterstock Urogen reports positive Phase III urinary tract cancer drug results

The company hopes to obtain FDA approval and launch its drug this year.

Tehila Ben Moshe Photo: Ophir Farkash Israeli co Biond Biologics raises $17m

The company is developing novel immunotherapies for cancer and autoimmune diseases.

Avram Hershko  photo: Vincent Ma "Do what's important, not what's fashionable"

Israeli Nobel laureate in chemistry Avram Hershko talks forthrightly about peace, democracy, academic independence, and how to do science.

Kare Schultz Photo: PR Schultz: Teva debt cut to $27b

After a year in the job, the Teva CEO says there will be no more acquisitions until the debt is reduced further but also no more sell-off of activities.

Teva workers demonstrate in Kiryat Shmona FIMI in talks to buy Teva's Kiryat Shmona plant

Medical equipment company Migada has been valued in the tens of millions of dollars.

Avner Halperin Photo: Eyal Yizhar Patient monitoring co EarlySense raises $39m

Most of the latest financing round in the Israeli company was invested by hospital bed manufacturer Hill-Rom.

Dr. Alan Schwebel Photo: Eyal Izhar BioView signs Chinese distribution deal worth NIS 70m

The Israeli company's imaging systems are used in Chinese company Livzon Cynvenio Diagnostics' blood test for early detection of lung cancer.

Sam Topaz Photo: PR Accelmed's Keystone Dental merges with Israel's Paltop

US dental implant company Keystone Dental has merged with Israeli company Paltop and Accelmed has led a $20 million investment in the merged company.

Dan Weinthal and Dr. Yoel Shiboleth Photo: Haim Varsano TargetGene develops more precise gene editing

The Israeli company's solution takes the new CRISPR gene-cutting technology one better.

Ori Hadomi Photo: Eyal Izhar "Raising the price increased demand for our device"

Mazor Robotics CEO Ori Hadomi tells the 17-year story that led to the robotic surgery company's $1.64 billion exit.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018